FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032281019> ?p ?o ?g. }

• W3032281019 endingPage "5517" @default.
• W3032281019 startingPage "5517" @default.
• W3032281019 abstract "5517 Background: Rapid cycling between high and low testosterone (T) (i.e BAT) produces tumor response in mCRPC, and may overcome resistance to newer AR therapies. Here we report a randomized study comparing BAT to E in men with mCRPC progressing on abiraterone (A). Methods: In this phase 2 trial, men received either T cypionate 400mg IM (BAT) once every 28 days or daily oral E 160mg. Primary endpoint was clinical/radiographic PFS; crossover was permitted at progression. Secondary endpoints were OS, PSA progression to primary and crossover therapy, PSA and objective responses (OR), time to PSA progression from randomization through crossover (PFS2), quality of life (QoL), and AEs. Results: 195 men were randomized (94 to BAT, 101 to E). Results are presented in table. Although diametrically opposed therapies, median PFS and PSA response in the intent-to-treat (ITT) population was not significantly different between BAT and E. OR and OS favored BAT. For those who received BAT and then crossed over to E the PSA50 response was 77.8% and time to PSA progression was 10.9 mo compared to 25.3% and 3.8 mo for those receiving E immediately after A. The sequence of treatment had a significant effect on median PSF2 which was 28.2 mo for men receiving BAT→E vs. 19.6 m for E→BAT. For men who crossed over from BAT to E, OS was 37.3 mo vs. 28.6 months for those receiving E without crossover. AEs were primarily grade 1-2 in the BAT arm and included fatigue, generalized pain, and lower extremity edema. BAT improved QoL (fatigue, physical functioning, sexual function) vs. E. Conclusions: BAT could be safely administered to asymptomatic men with mCRPC. BAT produced a comparable PFS to E in A-refractory mCRPC pts. However, PSA50 and OR after crossover, as well as PFS2, were significantly improved in men who received BAT→E versus E→BAT. OS in men receiving BAT→E was 37.3 mo, exceeding historical expectations. These results support the hypothesis that treatment with BAT is safe, has efficacy and can restore sensitivity to antiandrogens. Clinical trial information: NCT02286921 . [Table: see text]" @default.
• W3032281019 created "2020-06-05" @default.
• W3032281019 creator A5000331138 @default.
• W3032281019 creator A5001771354 @default.
• W3032281019 creator A5001783218 @default.
• W3032281019 creator A5004935250 @default.
• W3032281019 creator A5012074439 @default.
• W3032281019 creator A5013015133 @default.
• W3032281019 creator A5014339741 @default.
• W3032281019 creator A5033904513 @default.
• W3032281019 creator A5045477158 @default.
• W3032281019 creator A5049066344 @default.
• W3032281019 creator A5065094159 @default.
• W3032281019 creator A5068080767 @default.
• W3032281019 creator A5071773606 @default.
• W3032281019 creator A5075880342 @default.
• W3032281019 creator A5077312194 @default.
• W3032281019 creator A5078252133 @default.
• W3032281019 creator A5080102032 @default.
• W3032281019 creator A5080507578 @default.
• W3032281019 creator A5088048189 @default.
• W3032281019 creator A5088312939 @default.
• W3032281019 date "2020-05-20" @default.
• W3032281019 modified "2023-10-14" @default.
• W3032281019 title "TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC)." @default.
• W3032281019 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.5517" @default.
• W3032281019 hasPublicationYear "2020" @default.
• W3032281019 type Work @default.
• W3032281019 sameAs 3032281019 @default.
• W3032281019 citedByCount "2" @default.
• W3032281019 countsByYear W30322810192021 @default.
• W3032281019 countsByYear W30322810192022 @default.
• W3032281019 crossrefType "journal-article" @default.
• W3032281019 hasAuthorship W3032281019A5000331138 @default.
• W3032281019 hasAuthorship W3032281019A5001771354 @default.
• W3032281019 hasAuthorship W3032281019A5001783218 @default.
• W3032281019 hasAuthorship W3032281019A5004935250 @default.
• W3032281019 hasAuthorship W3032281019A5012074439 @default.
• W3032281019 hasAuthorship W3032281019A5013015133 @default.
• W3032281019 hasAuthorship W3032281019A5014339741 @default.
• W3032281019 hasAuthorship W3032281019A5033904513 @default.
• W3032281019 hasAuthorship W3032281019A5045477158 @default.
• W3032281019 hasAuthorship W3032281019A5049066344 @default.
• W3032281019 hasAuthorship W3032281019A5065094159 @default.
• W3032281019 hasAuthorship W3032281019A5068080767 @default.
• W3032281019 hasAuthorship W3032281019A5071773606 @default.
• W3032281019 hasAuthorship W3032281019A5075880342 @default.
• W3032281019 hasAuthorship W3032281019A5077312194 @default.
• W3032281019 hasAuthorship W3032281019A5078252133 @default.
• W3032281019 hasAuthorship W3032281019A5080102032 @default.
• W3032281019 hasAuthorship W3032281019A5080507578 @default.
• W3032281019 hasAuthorship W3032281019A5088048189 @default.
• W3032281019 hasAuthorship W3032281019A5088312939 @default.
• W3032281019 hasConcept C121608353 @default.
• W3032281019 hasConcept C126322002 @default.
• W3032281019 hasConcept C126894567 @default.
• W3032281019 hasConcept C142724271 @default.
• W3032281019 hasConcept C143998085 @default.
• W3032281019 hasConcept C168563851 @default.
• W3032281019 hasConcept C203092338 @default.
• W3032281019 hasConcept C204243189 @default.
• W3032281019 hasConcept C204787440 @default.
• W3032281019 hasConcept C27081682 @default.
• W3032281019 hasConcept C2776551883 @default.
• W3032281019 hasConcept C2776694085 @default.
• W3032281019 hasConcept C2780192828 @default.
• W3032281019 hasConcept C2780739268 @default.
• W3032281019 hasConcept C2908647359 @default.
• W3032281019 hasConcept C61367390 @default.
• W3032281019 hasConcept C71924100 @default.
• W3032281019 hasConcept C87813604 @default.
• W3032281019 hasConcept C99454951 @default.
• W3032281019 hasConceptScore W3032281019C121608353 @default.
• W3032281019 hasConceptScore W3032281019C126322002 @default.
• W3032281019 hasConceptScore W3032281019C126894567 @default.
• W3032281019 hasConceptScore W3032281019C142724271 @default.
• W3032281019 hasConceptScore W3032281019C143998085 @default.
• W3032281019 hasConceptScore W3032281019C168563851 @default.
• W3032281019 hasConceptScore W3032281019C203092338 @default.
• W3032281019 hasConceptScore W3032281019C204243189 @default.
• W3032281019 hasConceptScore W3032281019C204787440 @default.
• W3032281019 hasConceptScore W3032281019C27081682 @default.
• W3032281019 hasConceptScore W3032281019C2776551883 @default.
• W3032281019 hasConceptScore W3032281019C2776694085 @default.
• W3032281019 hasConceptScore W3032281019C2780192828 @default.
• W3032281019 hasConceptScore W3032281019C2780739268 @default.
• W3032281019 hasConceptScore W3032281019C2908647359 @default.
• W3032281019 hasConceptScore W3032281019C61367390 @default.
• W3032281019 hasConceptScore W3032281019C71924100 @default.
• W3032281019 hasConceptScore W3032281019C87813604 @default.
• W3032281019 hasConceptScore W3032281019C99454951 @default.
• W3032281019 hasIssue "15_suppl" @default.
• W3032281019 hasLocation W30322810191 @default.
• W3032281019 hasOpenAccess W3032281019 @default.
• W3032281019 hasPrimaryLocation W30322810191 @default.
• W3032281019 hasRelatedWork W1968987454 @default.
• W3032281019 hasRelatedWork W2247731044 @default.
• W3032281019 hasRelatedWork W2309274182 @default.

• next